Overview
| Uniprot ID | P15428 |
|---|
| Protein Name | 15-hydroxyprostaglandin dehydrogenase [NAD(+)] |
|---|
| Gene Name | HPGD |
|---|
| Organism | Homo sapiens |
|---|
Kla Sites from experimental identification
| Position |
Flanking peptide |
| 264 |
DTTPFQAKTQ***** |
Function
Catalyzes the NAD-dependent dehydrogenation (oxidation) of a broad array of hydroxylated polyunsaturated fatty acids (mainly eicosanoids and docosanoids, including prostaglandins, lipoxins and resolvins), yielding their corresponding keto (oxo) metabolites (PubMed:10837478, PubMed:16757471, PubMed:16828555, PubMed:21916491, PubMed:25586183, PubMed:8086429). Decreases the levels of the pro-proliferative prostaglandins such as prostaglandin E2 (whose activity is increased in cancer because of an increase in the expression of cyclooxygenase 2) and generates oxo-fatty acid products that can profoundly influence cell function by abrogating pro-inflammatory cytokine expression (PubMed:15574495, PubMed:25586183). Converts resolvins E1, D1 and D2 to their oxo products, which represents a mode of resolvin inactivation. Resolvin E1 plays important roles during the resolution phase of acute inflammation, while resolvins D1 and D2 have a unique role in obesity-induced adipose inflammation (PubMed:16757471, PubMed:22844113)
Protein Sequence
10
MHVNGKVALV
20
TGAAQGIGRA
30
FAEALLLKGA
40
KVALVDWNLE
50
AGVQCKAALD
60
EQFEPQKTLF
70
IQCDVADQQQ
80
LRDTFRKVVD
90
HFGRLDILVN
100
NAGVNNEKNW
110
EKTLQINLVS
120
VISGTYLGLD
130
YMSKQNGGEG
140
GIIINMSSLA
150
GLMPVAQQPV
160
YCASKHGIVG
170
FTRSAALAAN
180
LMNSGVRLNA
190
ICPGFVNTAI
200
LESIEKEENM
210
GQYIEYKDHI
220
KDMIKYYGIL
230
DPPLIANGLI
240
TLIEDDALNG
250
AIMKITTSKG
260
IHFQDYDTTP
FQAKTQ
Gene Ontology
| Classification |
GO ID |
Description |
| Cellular Component |
GO:0016323 |
basolateral plasma membrane |
| Cellular Component |
GO:0005737 |
cytoplasm |
| Cellular Component |
GO:0005829 |
cytosol |
| Cellular Component |
GO:0070062 |
extracellular exosome |
| Molecular Function |
GO:0047034 |
15-hydroxyicosatetraenoate dehydrogenase activity |
| Molecular Function |
GO:0016404 |
15-hydroxyprostaglandin dehydrogenase (NAD+) activity |
| Molecular Function |
GO:0042802 |
identical protein binding |
| Molecular Function |
GO:0051287 |
NAD binding |
| Molecular Function |
GO:0070403 |
NAD+ binding |
| Molecular Function |
GO:0016616 |
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor |
| Molecular Function |
GO:0004957 |
prostaglandin E receptor activity |
| Biological Process |
GO:0097070 |
ductus arteriosus closure |
| Biological Process |
GO:0007565 |
female pregnancy |
| Biological Process |
GO:0001822 |
kidney development |
| Biological Process |
GO:2001301 |
lipoxin biosynthetic process |
| Biological Process |
GO:0019372 |
lipoxygenase pathway |
| Biological Process |
GO:0045786 |
negative regulation of cell cycle |
| Biological Process |
GO:0030728 |
ovulation |
| Biological Process |
GO:0007567 |
parturition |
| Biological Process |
GO:0043065 |
positive regulation of apoptotic process |
| Biological Process |
GO:1904707 |
positive regulation of vascular associated smooth muscle cell proliferation |
| Biological Process |
GO:1905344 |
prostaglandin catabolic process |
| Biological Process |
GO:0006693 |
prostaglandin metabolic process |
| Biological Process |
GO:1905828 |
regulation of prostaglandin catabolic process |
| Biological Process |
GO:0032355 |
response to estradiol |
| Biological Process |
GO:0045471 |
response to ethanol |
| Biological Process |
GO:0032496 |
response to lipopolysaccharide |
| Biological Process |
GO:0070493 |
thrombin-activated receptor signaling pathway |
| Biological Process |
GO:0007179 |
transforming growth factor beta receptor signaling pathway |
Reference
[1] Yang Z, Yan C, Ma J, Peng P, Ren X et al.. Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma.. Nat Metab 5(1):61-79. 2023 Jan. PMID: 36593272.